Enhancing Prescription Drug Innovation and Adoption

被引:19
作者
Alexander, G. Caleb
O'Connor, Alec B.
Stafford, Randall S.
机构
[1] Univ Chicago, Univ Chicago Hosp, Chicago, IL 60637 USA
[2] Univ Illinois, Sch Pharm, Chicago, IL USA
[3] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
基金
美国医疗保健研究与质量局;
关键词
SURROGATE END-POINTS; CLINICAL-TRIALS; FDA; RISK; INFORMATION;
D O I
10.7326/0003-4819-154-12-201106210-00012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The adoption and use of a new drug would ideally be guided by its innovation and cost-effectiveness. However, information about the relative efficacy and safety of a drug is typically incomplete even well after market entry, and various other forces create a marketplace in which most new drugs are little better than their older counterparts. Five proposed mechanisms are considered for promoting innovation and reducing the use of therapies ultimately found to offer poor value or have unacceptable risks. These changes range from increasing the evidence required for U. S. Food and Drug Administration approval to modifying the structure of drug reimbursement. Despite the challenges of policy implementation, the United States has a long history of successfully improving the societal value and safe use of prescription medicines.
引用
收藏
页码:833 / 839
页数:7
相关论文
共 37 条
  • [1] A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy
    Abraham, J
    Davis, C
    [J]. SOCIAL SCIENCE & MEDICINE, 2005, 61 (05) : 881 - 892
  • [2] Does Comparative Effectiveness Have a Comparative Edge?
    Alexander, G. Caleb
    Stafford, Randall S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (23): : 2488 - 2490
  • [3] *ASTRAZENECA, 2010, 4 Q FULL YEAR RES 20
  • [4] BACIU A, 2007, FUTURE DRUG SAFETY P
  • [5] Effects of torcetrapib in patients at high risk for coronary events
    Barter, Philip J.
    Caulfield, Mark
    Eriksson, Mats
    Grundy, Scott M.
    Kastelein, John J. P.
    Komajda, Michel
    Lopez-Sendon, Jose
    Mosca, Lori
    Tardif, Jean-Claude
    Waters, David D.
    Shear, Charles L.
    Revkin, James H.
    Buhr, Kevin A.
    Fisher, Marian R.
    Tall, Alan R.
    Brewer, Bryan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
  • [6] Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates
    Berndt, ER
    Gottschalk, AHB
    Philipson, TJ
    Strobeck, MW
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (07) : 545 - 554
  • [7] Carpenter D, 2010, PRINC STUD AM POLIT, P1
  • [8] Surrogate end points in clinical trials: Are we being misled?
    Fleming, TR
    DeMets, DL
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 605 - 613
  • [9] Back to thiazide-diuretics for hypertension: Reflections after a decade of irrational prescribing
    Atle Fretheim
    [J]. BMC Family Practice, 4 (1) : 1 - 4
  • [10] Green J.A., 2007, Prescribing by the Numbers